GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (FRA:0RA) » Definitions » Short-Term Debt

RAPT Therapeutics (FRA:0RA) Short-Term Debt : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics Short-Term Debt?

RAPT Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.


RAPT Therapeutics Short-Term Debt Historical Data

The historical data trend for RAPT Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics Short-Term Debt Chart

RAPT Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

RAPT Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

RAPT Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


RAPT Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


RAPT Therapeutics (FRA:0RA) Business Description

Traded in Other Exchanges
Address
561 Eccles Avenue, South San Francisco, CA, USA, 94080
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics (FRA:0RA) Headlines

No Headlines